A Phase 1 Study of INCA033989 in People With Myeloproliferative Neoplasms


Full Title

A Phase 1, Open-Label, Multicenter Study of INCA033989 in Participants With Myeloproliferative Neoplasms


Researchers want to find the best dose of INCA033989 to use in people with myelofibrosis (MF) and essential thrombocytopenia (ET). These diseases are called myeloproliferative neoplasms. The people in this study have myeloproliferative neoplasms that came back or keep growing even after treatment. In addition, their cancers have a mutation (change or variant) in the CALR exon-9 gene.

INCA033989 blocks a protein that can cause cancer cells to grow. By blocking this protein, INCA033989 may help slow or stop the growth of your cancer. INCA033989 is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have MF or ET that came back or keeps growing even after treatment and has a CALR exon-9 mutation.
  • Have completed prior therapy at least 4 weeks before getting INCA033989.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information and to see if you can join this study, please call Dr. Raajit Rampal’s office at 646-608-3746.




Phase I (phase 1)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID